tetano
Editor, Senior Moderator
J Med Virol
. 2021 Aug 18.
doi: 10.1002/jmv.27280. Online ahead of print.
Elevated Inflammatory Markers Are Associated With Poor Outcomes in COVID-19 Patients Treated With Remdesivir
Kate Stoeckle[SUP] 1 2 [/SUP], Britta Witting[SUP] 3 [/SUP], Shashi Kapadia[SUP] 3 2 [/SUP], Anjile An[SUP] 4 [/SUP], Kristen Marks[SUP] 3 2 [/SUP]
Affiliations
Abstract
The antiviral remdesivir has been shown to decrease length of hospital stay in COVID-19 patients requiring supplemental oxygen. However many patients decompensate despite being treated with remdesivir. To identify potential prognostic factors in remdesivir-treated patients, we performed a retrospective cohort study of patients hospitalized at New-York-Presbyterian Hospital/Weill Cornell Medical Center between March 23, 2020 and May 27, 2020. We identified 55 patients who were treated with remdesivir for COVID-19 and analyzed inflammatory markers and clinical outcomes. C-reactive protein, d-dimer and lactate dehydrogenase levels were significantly higher in patients who progressed to intubation or death by 14 days compared to those who remained stable. CRP levels decreased significantly after remdesivir administration in patients who remained non-intubated over the study period. To our knowledge, this is the largest study to date examining inflammatory markers before and after remdesivir administration. Our findings support further investigation into COVID-19 treatment strategies that modify the inflammatory response. This article is protected by copyright. All rights reserved.
Keywords: coronavirus disease 2019; inflammatory markers; remdesivir.
. 2021 Aug 18.
doi: 10.1002/jmv.27280. Online ahead of print.
Elevated Inflammatory Markers Are Associated With Poor Outcomes in COVID-19 Patients Treated With Remdesivir
Kate Stoeckle[SUP] 1 2 [/SUP], Britta Witting[SUP] 3 [/SUP], Shashi Kapadia[SUP] 3 2 [/SUP], Anjile An[SUP] 4 [/SUP], Kristen Marks[SUP] 3 2 [/SUP]
Affiliations
- PMID: 34406670
- DOI: 10.1002/jmv.27280
Abstract
The antiviral remdesivir has been shown to decrease length of hospital stay in COVID-19 patients requiring supplemental oxygen. However many patients decompensate despite being treated with remdesivir. To identify potential prognostic factors in remdesivir-treated patients, we performed a retrospective cohort study of patients hospitalized at New-York-Presbyterian Hospital/Weill Cornell Medical Center between March 23, 2020 and May 27, 2020. We identified 55 patients who were treated with remdesivir for COVID-19 and analyzed inflammatory markers and clinical outcomes. C-reactive protein, d-dimer and lactate dehydrogenase levels were significantly higher in patients who progressed to intubation or death by 14 days compared to those who remained stable. CRP levels decreased significantly after remdesivir administration in patients who remained non-intubated over the study period. To our knowledge, this is the largest study to date examining inflammatory markers before and after remdesivir administration. Our findings support further investigation into COVID-19 treatment strategies that modify the inflammatory response. This article is protected by copyright. All rights reserved.
Keywords: coronavirus disease 2019; inflammatory markers; remdesivir.